New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export NVO’s income statement to Excel — free account
Novo Nordisk A/S
NVOHealthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +3.87%
- EPS
- −17.1%
- Free cash flow
- −14.8%
- Total debt
- +30.7%
Quarter to September 2026, against a year earlier
38.69
0.20
−0.51%
Follow NVO
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 16,611 | 16,967 | 17,099 | 18,291 | 19,448 | 22,401 | 25,057 | 33,724 | 42,108 | 46,792 | 51,914 | +12.2% | — | — | — | — | |
| Gross margin, % | 84.63 | 84.21 | 84.25 | 83.54 | 83.51 | 83.20 | 83.92 | 84.60 | 84.67 | 80.98 | 80.89 | (3.7) pt | ||||||
| EBT | 7,103 | 7,394 | 7,280 | 7,278 | 8,140 | 9,400 | 9,779 | 15,199 | 18,443 | 19,764 | 22,619 | +12.0% | ||||||
| EBT margin, % | 42.76 | 43.58 | 42.58 | 39.79 | 41.85 | 41.96 | 39.03 | 45.07 | 43.80 | 42.24 | 43.57 | (0.5) pt | ||||||
| Net income | 5,636 | 5,792 | 5,906 | 5,839 | 6,456 | 7,598 | 7,862 | 12,151 | 14,643 | 15,509 | 16,967 | +11.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 3.28 | 3.43 | 3.53 | 3.85 | 4.17 | 4.88 | 5.53 | 7.52 | 9.45 | 10.53 | 11.78 | +13.8% | |||||
| Earnings | 1.07 | 1.17 | 1.27 | 1.23 | 1.39 | 1.66 | 1.74 | 2.71 | 3.29 | 3.49 | 3.97 | +14.0% | ||||||
| Cash flow | 1.42 | 1.26 | 1.41 | 1.48 | 1.71 | 1.90 | 2.47 | 3.53 | 3.94 | 4.06 | 4.36 | +12.4% | ||||||
| Capex | (0.24) | (0.27) | (0.39) | (0.35) | (0.72) | (0.26) | (0.46) | (1.26) | (1.67) | (3.07) | (2.80) | +32.6% | ||||||
| Free cash flow | 1.18 | 1.00 | 1.02 | 1.12 | 0.98 | 1.65 | 2.00 | 2.27 | 2.27 | 0.99 | 1.56 | (1.9%) | ||||||
| Book value | 1.33 | 1.53 | 1.64 | 1.82 | 2.08 | 2.45 | 2.61 | 3.45 | 4.67 | 6.61 | 7.61 | +19.5% | ||||||
| Shares, m | 5,060 | 4,946 | 4,839 | 4,749 | 4,668 | 4,594 | 4,531 | 4,483 | 4,454 | 4,443 | 4,431 | (1.4%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 16.11 | 23.24 | 18.21 | 23.53 | 25.40 | 33.84 | 39.47 | 37.75 | 26.15 | 14.66 | 9.80 | 25.8 | |||||
| P/S | 5.47 | 7.89 | 6.52 | 7.51 | 8.38 | 11.48 | 12.38 | 13.57 | 9.10 | 4.83 | 3.30 | 8.7 | ||||||
| P/B | 13.51 | 17.70 | 14.07 | 15.92 | 16.81 | 22.86 | 26.24 | 29.58 | 18.41 | 7.69 | 5.11 | 18.3 | ||||||
| EV/Sales | 5.28 | 7.72 | 6.38 | 7.42 | 8.36 | 11.54 | 12.38 | 13.55 | 9.34 | 5.15 | 3.55 | 8.7 | ||||||
| EV/FCF | 14.74 | 26.51 | 22.16 | 25.47 | 35.54 | 34.12 | 34.16 | 44.95 | 38.94 | 54.86 | 26.82 | 33.1 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 7,179 | 6,253 | 6,822 | 7,013 | 7,959 | 8,751 | 11,170 | 15,813 | 17,540 | 18,032 | 19,207 | +10.8% | |||||
| Capex | (1,227) | (1,312) | (1,896) | (1,683) | (3,382) | (1,175) | (2,089) | (5,648) | (7,440) | (13,643) | (12,328) | +30.7% | ||||||
| Free cash flow | 5,952 | 4,941 | 4,926 | 5,330 | 4,577 | 7,576 | 9,081 | 10,166 | 10,101 | 4,389 | 6,879 | (3.3%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 1,832 | 1,978 | 750 | 521 | (684) | (2,215) | (1,805) | (4,357) | (8,211) | (6,542) | (5,957) | n/m | |||||
| Net debt | (3,120) | (2,956) | (2,343) | (1,676) | (368) | 1,188 | (73) | (808) | 10,172 | 14,733 | 13,171 | n/m | ||||||
| Shareholders’ equity | 6,727 | 7,567 | 7,926 | 8,633 | 9,701 | 11,256 | 11,822 | 15,473 | 20,805 | 29,379 | 33,542 | +17.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 40.03 | 38.56 | 36.36 | 32.65 | 31.47 | 28.59 | 24.15 | 30.44 | 25.87 | 20.71 | 20.52 | (19.3) pt | |||||
| ROIC | 124.72 | 100.83 | 80.88 | 70.67 | 55.53 | 46.86 | 56.35 | 63.48 | 37.55 | 27.38 | 29.63 | (97.3) pt | ||||||
| ROE | 82.18 | 81.04 | 76.24 | 70.52 | 70.42 | 72.51 | 68.14 | 89.04 | 80.73 | 61.81 | 58.84 | (20.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 41,971 | 42,076 | 43,202 | 43,258 | 45,323 | 45,000 | 55,185 | 63,370 | 77,349 | 69,505 | — | +5.8% | |||||
| Revenue/emp, $m | 0.40 | 0.40 | 0.40 | 0.42 | 0.43 | 0.50 | 0.45 | 0.53 | 0.54 | 0.67 | — | +6.1% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026
Novo Nordisk A/S vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NVS Novartis AG | $277.7B | 28.8× | 24.0× FY26e | +4.67% (above 0%: growing) | −68.81% (below 0%: shrinking) | −17.81% (below 0%: shrinking) | 75.99% | 12.26% | Compare |
| AZN AstraZeneca PLC | $272.1B | 24.6× | 24.2× FY26e | +6.70% (above 0%: growing) | +23.46% (above 0%: growing) | +1.99% (above 0%: growing) | 81.82% | 27.07% | Compare |
| AMGN Amgen Inc. | $237.4B | 25.2× | 24.0× FY26e | +8.45% (above 0%: growing) | +19.39% (above 0%: growing) | −13.98% (below 0%: shrinking) | 73.10% | 35.79% | Compare |
| GILD Gilead Sciences, Inc. | $207.8B | — (loss-making) | — (loss-making) | +6.83% (above 0%: growing) | −20.16% (below 0%: shrinking) | +21.13% (above 0%: growing) | 81.07% | 41.71% | Compare |
| PFE Pfizer Inc. | $158.2B | 38.8× | 18.7× FY26e | −0.43% (below 0%: shrinking) | −9.68% (below 0%: shrinking) | +20.02% (above 0%: growing) | 75.71% | 22.14% | Compare |
| NVO Novo Nordisk A/S | $128.6B | 9.8× | — | +3.87% (above 0%: growing) | −17.14% (below 0%: shrinking) | −14.75% (below 0%: shrinking) | 76.97% | 29.06% | |
| BMY Bristol Myers Squibb Company | $119.3B | 12.9× | 12.0× FY26e | +6.93% (above 0%: growing) | −2.78% (below 0%: shrinking) | −35.95% (below 0%: shrinking) | 68.28% | 19.40% | Compare |
| SNY Sanofi | $111.3B | 22.8× | — | +13.89% (above 0%: growing) | +8.21% (above 0%: growing) | +99.60% (above 0%: growing) | 76.16% | 28.53% | Compare |
| GSK GSK PLC Sponsored ADR | $95.9B | 16.4× | 15.5× FY26e | +3.75% (above 0%: growing) | −23.88% (below 0%: shrinking) | +62.44% (above 0%: growing) | 73.11% | 23.93% | Compare |
| Median of peers | $183.0B | 24.6× | 21.4× | +6.77% | −6.23% | +11.01% | 75.85% | 25.50% |
Novo Nordisk A/S (NVO) Latest News
What happened
- Deal Novo Nordisk and nference partnered to use clinical-trial research and an AI platform to study cardiometabolic disease and healthy ageing.
- Product Novo Nordisk submitted US and European applications for etavopivat, an investigational sickle cell treatment that reduced vaso-occlusive crises by 27% in a Phase 3 trial.
- Product Novo Nordisk’s Wegovy pill surpassed eight million cumulative US prescriptions, while third-quarter sales reached DKK 5.4 billion.
- Legal Novo Nordisk was among the GLP-1 manufacturers asked by the FDA to add warnings about rare sudden vision loss from NAION.
- Results Novo Nordisk reported third-quarter sales of DKK 79.2 billion and raised its 2026 adjusted sales and operating profit growth outlook to -2% to 2%.
- Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine PR Newswire
- Novo Nordisk (CPSE:NOVO B) Scores Phase 3 Win And EU Approval Across New Therapies Simply Wall St +1 report
- Novo Nordisk Stock Rises on Obesity Drug Breakthrough GuruFocus +2 reports
- Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology PR Newswire +1 report
- Novo Nordisk (CPSE:NOVO B) Stock Faces Q3 Earnings Profit Squeeze Simply Wall St.
- NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook Zacks
- Novo Nordisk: 3 Key Takeaways for Long-Term Investors The Motley Fool
- Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know The Motley Fool
- Will Raised Outlook Change Novo Nordisk Stock Narrative Simply Wall St.
- Novo Nordisk AS (NVO) (Q3 2026) Earnings Call Highlights: Obesity Sales Surge 22% as Wegovy ... GuruFocus.com
12 more headlines
- Novo Up 4% in a Month: How Should Investors Approach the Stock Now? Zacks
- Novo Nordisk (NVO) Q3 2026 Earnings Call Transcript The Motley Fool transcript
- Novo Nordisk Stocks Rise 5.65% While Higher Guidance Meets Diverging Profit Measures GuruFocus.com
- Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone 24/7 Wall St.
- Wegovy CEO Reveals a Surprise in Weight-Loss Drug Race GuruFocus.com
- Novo’s Comeback Gets a Pill-Shaped Boost as Wegovy Starts to Bite Back Moby
- Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts biopharmadive.com
- Novo Nordisk (CPSE:NOVO B) Raised Its Outlook, Is The Stock Still Undervalued? Simply Wall St.
- Novo Nordisk outlook upgrade leaves forecasts lagging, Jefferies says Proactive Investors
- Novo Nordisk CEO: Wegovy pill 'exceeded our expectations'
- Novo Nordisk Raises 2026 Guidance as Obesity Drug Sales Rise 22% and Quarterly Earnings Beat Forecasts InvestorsHub
- NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised Zacks
NVO metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score